SynAct Pharma CEO Jeppe Øvlesen and newly appointed Chief Business Officer Mads Bjerregaard visit the BioStock studio to talk about the company's latest developments. In the interview, they share the background to the latest recruitment, Mads' role and priorities going forward, and how SynAct plans for future business development and market entry in line with progress in the ADVANCE phase IIb study in rheumatoid arthritis.
Watch the interview with the CEO Jeppe Ovlesenand CBO Mads Bjerregaardbelow.
The content of BioStock's news and analysis is independent, but BioStock's operations are to some extent financed by companies in the industry. This post refers to a company from which BioStock has received funding.